



ISFP General Assembly Minutes (Melbourne, Australia):

July 7th, 2019, Room 208

The convocation to the General Assembly was announced on the website of the ISFP in accordance with the Bylaws, and by e-mail to the members.

Future organization of the ISFP

- “International Society for Fibrinolysis and Proteolysis (ISFP)” (identification number 13963/2001; “Belgisch Staatsblad” Juli 26, 2001; corporation number 475.197.060) was dissolved in Belgium on October 1, 2018.
- “International Society for Fibrinolysis and Proteolysis” incorporated in Hamilton, Canada, on May 8, 2018, with the same objectives as the Belgian not-for-profit organization, and the same Bylaws with minor modifications as requested by the “Canada not-for-profit Corporations Act”.
- H.R. Lijnen discharged of management of ISFP as Executive Director on October 1, 2018.
- P.Y. Kim as the incoming Executive Director of ISFP Canada Inc.

Future Congresses

- ISFP Congress will resume in 2021 in order to avoid competing meetings. As previously, the official ISFP congress will be held every 2 years.
- The Congress will take place Sept 6 to Sept 10, 2021.
- Our next ISFP/Plasminogen Activation Workshop joint congress will be held in Caen, France (President: Dr. Denis Vivien), as approved by the Council.
- The potential of hosting joint congress with IFRS was proposed by M. De Maat. The challenge that IFRS is not on alternating years was brought up. Spoke briefly with Dr. Robert Ariens on the side, who indicated that IFRS would be flexible in its host years following 2020, so a joint meeting may certainly be a possibility.
- Open to accepting bids for ISFP 2023: The council suggested that ISFP should open up for accepting bids for the 2023 congress. The announcement will be made shortly through the website and membership email list.

Composition of the Council

- N. Mutch - Chairman until 2020
- M.P. Stoppelli - Vice-chairman elect, to become Chairman after the 2020 Council meeting
- R. Medcalf - Secretary-Treasurer until 2022
- P. Kim will be the new Executive Director, starting October 1, 2018

To combat the challenges/alterations in Council Composition:

- N. Mutch to stay as past-chair until 2022
- M.P. Stoppelli stays as past-chair until 2024
- 5 new council members elected in 2021 (Class of 2025) – 4 year mandate
- 3 positions of ex-officio members are filled



Ex-officio members J.A. Lisman (Associate Editor JTH) and M. De Maat (Liaison Officer IFRS) remain in office until 2020, and M. Colucci (previous Chairman) until 2021. K. Kolev is appointed to represent the SSC on Fibrinolysis of the ISTH in the Council.

J. Meijers, D. Vivien and R. Lijnen join the ISFP Advisory Board (2018).

Financial situation

The income statement and balance 2018 and the proposed budget for 2019 are proposed for approval. The membership fee for 2019 is \$90 CAD for 2019-2021 or \$160 CAD for 2019-2022 (One bonus year offered until Dec 31, 2019).

One ISFP travel grant (1500€) was awarded in 2017. At the 2018 congress, the ISFP Prize (10,000\$), was awarded to Prof. P. Declerck for outstanding contributions to the field. In addition five D. Collen Young Investigator Awards were given (6500€) and about 13,400€ was allowed for travel grants to the best rated abstracts. The seed money (19,164€) provided to the congress by ISFP was recovered depending on the final congress budget (\$27,924.03). Copies of money transfer will be sent to the Secretary Treasurer (R. Medcalf). After complete transfer, the current total asset is at \$152,739.21 (CND).

Membership

2 new regular members and 4 new junior members were accepted by the General Assembly; 43 full memberships were paid in 2018 (some paid in 2017 for 2 years); 32 junior memberships, 13 honorary members and 5 complimentary members are registered. To compensate for the pushback of ISFP congress, the council proposed to offer an additional year of membership if renewed before the end of 2019. In 2019, 3 full memberships were paid, which were for 3 years (2 years + 1 bonus).

Report from the Journal of Thrombosis and Haemostasis (by T. Lisman)

The journal is doing well, with essentially no changes in number of manuscripts submitted, acceptance rates, and time from submission to first decision in the last 5 years. The number of basic science manuscripts submitted remains to be much lower than the number of clinical manuscripts, and I encourage you all to submit your best basic science to JTH. The impact factor of the journal is also stable, currently at 4.9.

The editorial team will change in 2019, with David Lillicrap and Jim Morrissey taking over from Frits Rosendaal and Pieter Reitsma as editors-in-chief. Some of the associate editors will also change, but I will stay on as the associate editor on behalf of the ISFP.

I have recently launched a new journal category in which we aim to highlight papers relevant for the readership of JTH that have been published elsewhere. This new journal category is called 'Neighborhood Watch', and you can find examples in 2018 issues of JTH, with some explanation in the January editorial (<http://onlinelibrary.wiley.com/doi/10.1111/jth.13918/epdf>). Although the neighborhood Watches can be submitted on invitation only, I welcome proposals for papers to be discussed (and potential authors of the Neighborhood Watch) from the ISFP membership. If you think a paper might be of interest for a Neighborhood Watch, please contact me via j.a.lisman@umcg.nl.



International
Society for
Fibrinolysis and
Proteolysis

I thank the members of the ISFP for their active involvement as reviewers for the journal. The most active reviewers are invited to join the editorial board, and I am very happy to see members of the ISFP in the editorial board list.

R. Medcalf
Secretary-Treasurer

N. Mutch
Chairman

P. Kim
Executive Director